Clinical Trial Update: A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating SGN-CEACAM5C in adults with advanced solid tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastroesophageal Junction Adenocarcinoma
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma
• Small Cell Lung Cancer
• Stomach Cancer

Drugs mentioned

• SGN-CEACAM5C

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: RECRUITING